Martí Duran-Ferrer

Martí Duran-Ferrer

Auto-generated profile, based on publicly available information

Martí Duran-Ferrer

Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 June 2015 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
MKMarta Kulis
Marta Kulis
AMAngelika Merkel
Angelika Merkel
SHSimon Heath
Simon Heath
AQAna C Queirós
Ana C Queirós
RSRonald P Schuyler
Ronald P Schuyler
JMJosé I Martín-Subero
José I Martín-Subero

17 September 2020 in Blood
Verified
Journal Article
Open access
PDF file
FNFerran Nadeu
Ferran Nadeu
DMDavid Martin-Garcia
David Martin-Garcia
GCGuillem Clot
Guillem Clot
ADAnder Diaz-Navarro
Ander Diaz-Navarro
MDMartí Duran-Ferrer
Martí Duran-Ferrer
ECElias Campo
Elias Campo
Mantle cell lymphoma (MCL) is a mature B-cell neoplasm initially driven by CCND1 rearrangement with 2 molecular subtypes, conventional MCL (cMCL) and leukemic non-nodal MCL (nnMCL), that differ in their clinicobiological behavior. To identify the genetic and epigenetic alterations determining this diversity, we used whole-genome (n = 61) and exome (n = 21) sequencing (74% cMCL, 26% nnMCL) combined with transcriptome and DNA methylation profiles in the context of 5 MCL reference epigenomes. We identified that open and active chromatin at the major translocation cluster locus might facilitate the t(11;14)(q13;32), which modifies the 3-dimensional structure of the involved regions. This translocation is mainly acquired in precursor B cells mediated by recombination-activating genes in both MCL subtypes, whereas in 8% of cases the translocation occurs in mature B cells mediated by activation-induced cytidine deaminase. We identified novel recurrent MCL drivers, including CDKN1B, SAMHD1, BCOR, SYNE1, HNRNPH1, SMARCB1, and DAZAP1. Complex structural alterations emerge as a relevant early oncogenic mechanism in MCL, targeting key driver genes. Breakage-fusion-bridge cycles and translocations activated oncogenes (BMI1, MIR17HG, TERT, MYC, and MYCN), generating gene amplifications and remodeling regulatory regions. cMCL carried significant higher numbers of structural variants, copy number alterations, and driver changes than nnMCL, with exclusive alterations of ATM in cMCL, whereas TP53 and TERT alterations were slightly enriched in nnMCL. Several drivers had prognostic impact, but only TP53 and MYC aberrations added value independently of genomic complexity. An increasing genomic complexity, together with the presence of breakage-fusion-bridge cycles and high DNA methylation changes related to the proliferative cell history, defines patients with different clinical evolution.

21 May 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
RBRenée Beekman
Renée Beekman
VCVicente Chapaprieta
Vicente Chapaprieta
NRNúria Russiñol
Núria Russiñol
RVRoser Vilarrasa-Blasi
Roser Vilarrasa-Blasi
NVNúria Verdaguer-Dot
Núria Verdaguer-Dot
JMJose I. Martin-Subero
Jose I. Martin-Subero

4 August 2022 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
BKBinyamin A. Knisbacher
Binyamin A. Knisbacher
ZLZiao Lin
Ziao Lin
CHCynthia K. Hahn
Cynthia K. Hahn
FNFerran Nadeu
Ferran Nadeu
MDMartí Duran-Ferrer
Martí Duran-Ferrer
GGGad Getz
Gad Getz

11 August 2022 in Nature Medicine
Verified
Journal Article
Open access
PDF file
FNFerran Nadeu
Ferran Nadeu
RRRomina Royo
Romina Royo
RMRamon Massoni-Badosa
Ramon Massoni-Badosa
HPHeribert Playa-Albinyana
Heribert Playa-Albinyana
BGBeatriz Garcia-Torre
Beatriz Garcia-Torre
ECElías Campo
Elías Campo
Richter transformation (RT) is a paradigmatic evolution of chronic lymphocytic leukemia (CLL) into a very aggressive large B cell lymphoma conferring a dismal prognosis. The mechanisms driving RT remain largely unknown. We characterized the whole genome, epigenome and transcriptome, combined with single-cell DNA/RNA-sequencing analyses and functional experiments, of 19 cases of CLL developing RT. Studying 54 longitudinal samples covering up to 19 years of disease course, we uncovered minute subclones carrying genomic, immunogenetic and transcriptomic features of RT cells already at CLL diagnosis, which were dormant for up to 19 years before transformation. We also identified new driver alterations, discovered a new mutational signature (SBS-RT), recognized an oxidative phosphorylation (OXPHOS)high–B cell receptor (BCR)low-signaling transcriptional axis in RT and showed that OXPHOS inhibition reduces the proliferation of RT cells. These findings demonstrate the early seeding of subclones driving advanced stages of cancer evolution and uncover potential therapeutic targets for RT.

1 November 2016 in Cancer Cell
Verified
Journal Article
Open access
AQAna C. Queirós
Ana C. Queirós
RBRenée Beekman
Renée Beekman
RVRoser Vilarrasa-Blasi
Roser Vilarrasa-Blasi
MDMartí Duran-Ferrer
Martí Duran-Ferrer
GCGuillem Clot
Guillem Clot
JMJosé I. Martín-Subero
José I. Martín-Subero
We analyzed the in silico purified DNA methylation signatures of 82 mantle cell lymphomas (MCL) in comparison with cell subpopulations spanning the entire B cell lineage. We identified two MCL subgroups, respectively carrying epigenetic imprints of germinal-center-inexperienced and germinal-center-experienced B cells, and we found that DNA methylation profiles during lymphomagenesis are largely influenced by the methylation dynamics in normal B cells. An integrative epigenomic approach revealed 10,504 differentially methylated regions in regulatory elements marked by H3K27ac in MCL primary cases, including a distant enhancer showing de novo looping to the MCL oncogene SOX11. Finally, we observed that the magnitude of DNA methylation changes per case is highly variable and serves as an independent prognostic factor for MCL outcome.